Pro-inflammatory Interlekin-33 induces dichotomic effects on cell proliferation in normal gastric epithelium and gastric cancer

Laura Francesca Pisani[a], Gian Eugenio Tontini[bc], Carmine Gentile[b], Beatrice Marinoni[b], Isabella Teani[b], Nicoletta Nandi[b], Pasquale Creo[a], Emanuele Asti[ab], Luigi Bonavina[ab], Maurizio Vecchi[cd], Luca Pastorelli[ab*].

[a] IRCCS Policlinico San Donato –   Via Morandi,30 - San Donato Milanese (Italy)

[b] Università degli Studi di Milano – Department of Biomedical Science for Health – Via Mangiagalli, 31 - Milano (Italy)

[c] IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano – Via Francesco Sforza, 28 - Milano (Italy)

[d] Università degli Studi di Milano – Department of Pathophysiology and Trasplantation – Via Francesco Sforza, 35 - Milano (Italy)

[*] Corresponding author

Luca Pastorelli, MD, PhD

IRCCS Policlinico San Donato

Via Morandi, 30 - San Donato Milanese (Italy)

Phone: +39 0252774683

e-mail: luca.pastorelli@unimi.it

Abstract

Background: Interleukin (IL)-33 is a member of interleukin (IL)-1 family of cytokines which has been linked to the development of inflammatory conditions and cancer in the gastrointestinal tract. This study is designed to investigate whether IL-33 has direct effect on human gastric epithelial cells (GES-1) and on human gastric adenocarcinoma cell line (AGS), assessing its role in regulation of cell proliferation and cell cycle, apoptosis and necrosis. Cell cycle regulation was also determined in ex vivo gastric cancer samples obtained during endoscopy and surgical procedures. Methods: cell lines and tissue samples underwent

stimulation with rhIL-33. Proliferation was assessed by XTT and CFSE assay, we also evaluated apoptosis and necrosis by Caspase 3/8 Activity assay and Propidium Iodine/Annexin V assays. Cell cycle were analyzed by means of Propidium Iodine assay and gene expression regulation was assessed by RT-PCR Profiling. Results: we found that IL-33 has an antiproliferative and proapoptotic effect on cancer cell line, while it can stimulate proliferation and reduce apoptosis in normal epithelial cell line. These effects are also confirmed by the analysis of cell cycle gene expression which showed a reduced expression of proproliferative genes in AGS cells, in particular genes involved in G0/G1 and G2/M checkpoint. These results are confirmed by the gene expression analysis on surgical and bioptic specimens. Conclusions: the aforementioned results indicate that IL-33 may be involved in cell proliferation in an environment- and cell type-dependent fashion.

Keywords: interleukin-33; gastric epithelium; proliferation; apoptosis; cell cycle; gastric cancer

Introduction

Gastric cancer is a leading cause of cancer-related deaths and is the fourth most common type of cancer in the world (1). The overall survival at 5-years of gastric cancer patients is only about 20% (2). Major risks for the development of gastric cancer are *Helicobacter pylori* infections, dietary factors and chronic gastritis (2).

The development of gastric cancer is a complex, multistep process involving multiple alterations in oncogenes, tumor suppressor genes, DNA repair genes, cell cycle regulators, and signaling molecules; thus, the pathways that lead to the transformation towards gastric cancer still need to be fully dissected (3, 4). Indeed, chronic inflammation plays a major role and pro-inflammatory cytokines appear to promote progression from gastritis to cancer; in particular, interleukin (IL)-1 family members, such as IL-1β and IL-18 have been shown to induce gastric cancerogenesis in animal models (5, 6).

IL-33 was identified as a new member of the IL-1 cytokine family and exerts its biological effects through the binding of its receptor, ST2, also known as IL-1 receptor-like 1 (IL1RL1), belonging to the Toll-IL-1 Receptor (TIR) superfamily (5, 7). IL-33 appears to be a cytokine with dual function, acting both as a

traditional cytokine and as an intracellular nuclear factor with transcriptional regulatory properties and is involved in Gastrointestinal (GI) tract epithelial repair and restitution, and to promote mucosal healing (8, 9). IL-33 is broadly expressed in many tissues, but its expression appears to be restricted by cell type (5). Expression analysis of human and mouse cDNA libraries revealed high expression of IL-33 mRNA in barrier epithelia within organs/tissues in direct contact with the external environment, including the skin, airway, and gut epithelia, suggesting a possible role of this cytokine in early immune responses against invasive pathogens (5). At the cellular level IL-33 is predominantly present in stromal cells including fibroblasts, smooth muscle cells, endothelial and epithelial cells (10) and also in restricted population of hematopoietic cells, such as macrophages (5, 11).

Moreover, several studies show that normal mice injected with recombinant IL-33 develop a marked epithelial cell hyperplasia throughout the whole gastrointestinal tracts, features of spasmolytic polypeptide-expressing metaplasia in the stomach, together with infiltration into the lamina propria of eosinophils and mononuclear cells and sustained chronic Th2-driven inflammation (12-14).

The role of IL-33 in neoplasia has been poorly investigated but different studies reported both pro- and anti-tumorigenic functions (17). It has been hypothesized that IL-33 has pro-tumorigenic function in cancer cell lines inducing an increase in invasion, migration (3, 18) and chemoresistance (19). In vivo, the protein seems to be less abundant in gastric tumor tissues than in surrounding normal tissue and it did not correlate to patients prognosis (20). These contrasting results suggest that the role of IL-33 in cancer development and growth is still to be clarified. In order to unravel some of these aspects we investigated whether IL-33 has effects on cell cycle and apoptosis in *in vitro* and *ex vivo* settings.

Materials and Methods

Cell lines and treatments

Human gastric epithelial cells GES-1 cell line (Courtesy of Prof. Hong Cai Beijing Cancer Hospital, China), was cultured in RPMI-1640 (Sigma-Aldrich, Italy) supplemented with 10% Fetal Bovine Serum (FBS), 1% antibiotic solution (100U/ml penicillin, 100mg/ml streptomycin) at 37°C in a 5% CO_2 humidified

atmosphere. Gastric adenocarcinoma cell line AGS (ATCC® CRL-1739™) was cultured in F12 nutrient mix, Kaighn's Modification (Life Technology, Italy) supplemented with 10% FBS and 1% antibiotic solution (100U/ml penicillin, 100mg/ml streptomycin) at 37°C in a 5% CO_2 humidified atmosphere. GES-1 and AGS cells were plated at $2.5*10^5$/ml; after 2 days the cells reached 70% confluence and were used for the treatments. Cells were challenged with growing concentrations of recombinant human IL-33 (Alexis, Vinci Biochem, Italy) at 37°C, for the incubation times indicated in the figure legends; rhIL-33 were suspended in sterile water and then diluted in complete medium specific for each cell line and added to cells to reach different final concentrations (0.1ng/ml, 1ng/ml and 10ng/ml). In the control groups, cells were incubated with the same amount of complete medium without rhIL-33.

Wound healing

GES-1 and AGS were grown to confluence in μ-Dish 35mm, low (Ibidi, Germany). The biocompatible silicone insert allows cells to grow in two separate chambers making a gap of 500μm ± 50μm. Medium was replaced by complete medium and medium with rhIL-33 (0h time point). Images were taken at 0, 6h and 24h and cell migration distance was determined by subtracting values obtained at 0h from each time point. Migration distances were expressed as percentages over control values.

Evaluation of cell proliferation

Cell proliferation was evaluated using XTT Cell Proliferation Assay Kit (ATCC, Italy) on $5*10^5$ cells/well. Cells were seeded in 96-well plates in triplicates in 100μL of complete medium 18 hours before stimulation. Then different concentrations of rhIL-33 were added to cells and incubated for 4 days. Activated-XTT Solution was prepared adding 100μL of the Activation Reagent to 5.0 mL of the XTT Reagent. Fifty μL of the Activated-XTT Solution was added to each well and the plate was returned to the CO_2 incubator for the optimized-assay incubation time. Formazan formation was evaluated recording absorbance at 450nm wavelength using a microplate reader (Victor 3; Perkin-Elmer, USA), and expressed as mean absorbance ± SEM.

Cell proliferation rate was also determined using flow cytometric analysis with CellTrace™ CFSE Cell Proliferation Kit (Life Technologies, Italy). Each daughter cell inherits approximately half of the fluorescent dye from the parental cell, hence allowing the quantification of cell divisions by the progressive decrease of CFSE fluorescence at different time intervals. Cells were harvested by trypsin digestion, washed three times and resuspended in 2ml PBS. Two microliters of CFSE stock solution was applied to 1 ml cells to get a final concentration of 10μM. Cells were incubated for 10 min at 37°C. The staining was quenched by the addition of 5-volumes of ice-cold complete medium and incubated for 5 min in ice. Cells were washed two times and resuspended in complete medium with different rhIL-33 concentrations and further cultured up to 4 or 6 days.

Cell cycle analysis by propidium-iodine (PI) staining

Cells were trypsinized and washed once in PBS to remove residual serum and trypsin. Cell number per sample should be 1.5×10^6 cells. Cells were resuspended in cold 70% ethanol drop by drop while vortexing and fixed for 30 minutes in ice. Cells were then spinned at 850g, 5 min, 4°C, washed once in PBS, spinned at at 850g, 5 min, 4°C and resuspend in PBS added with 1% Bovine Serum Albumin (BSA), spinned at 850g, 5 min, 4°C and resuspend in 500μl of PBS with 1% BSA and 0.1% Tween.

Cells were then incubated for 15min with RNAse A followed by the addition of 10μl of Propidium Iodine.

Cell cycle analysis was performed by flow cytometer (PerkinElmer, Italy).

Analysis of cell cycle by RT² Profiler PCR Array for Cell Cycle

Human Cell Cycle RT2 Profiler PCR Array (PAHS-0820, SABiosciences, Qiagen, Italy) was used to evaluate the expression of 84 specific genes related to cell cycle. After 24 hours of culture with rhIL-33 (10ng/ml) and without any challenge, total RNA was isolated using the miRNeasy Mini kit (Qiagen, Italy) according to the manufacturer's instructions. cDNA was synthesized from 500 ng of the total RNA using the RT2 First Strand Kit (Qiagen, Italy), which includes the additional removal of genomic DNA from the RNA sample and a specific control of reverse transcription. After all control tests, the samples were analysed using the RT2

Profiler PCR Array. Altogether, 84 different genes were simultaneously amplified in the sample. A melting curve analysis was performed to verify that the product consisted of a single amplicon. PCR arrays were performed in 96-well plates on a StepOne Plus instrument (Applied Biosystems, Italy). Briefly, the reaction mix was prepared from 2x SABiosciences RT2 qPCR Master Mix and 102µl of sample cDNA. 10µl of this mixture was added into each well of the PCR Array. The thresholds and baselines were set according to the manufacturer's instructions and data were analysed using software supplied by Qiagen (http://www.sabiosciences.com/pcr/arrayanalysis.php). The fold change in gene expression compared to unstimulated control was calculated using the ΔΔCt method. A more than 1.5 fold change in gene expression compared to unstimulated control was considered as the up- or downregulation of a specific gene expression. The gene pathway modified by IL-33 was reconstructed by IPA Software (SABiosciences, Qiagen, Italy). The genes differentially expressed in the two cell lines have been tested by qRT-PCR.

Evaluation of caspases-3 and caspase-7 activities

Following 6h and 24h treatments cells were subjected to Caspase 3/7 activities measurement with Caspase-Glo assay kit (Promega, Italy). Briefly, the plates containing cells were removed from the incubator and allowed to equilibrate to room temperature for 30 minutes. 100µl of Caspase-Glo reagent was added to each well, the content of well was gently mixed with a plate shaker at 300–500 rpm for 30 seconds. The plate was then incubated at room temperature for 2 hours. The luminescence of each sample was measured in a plate-reading luminometer (Victor 3; Perkin-Elmer, USA) with parameters of 1 minute lag time and 0.5 second/well read time. The experiments were performed in triplicate and repeated on three separately-initiated cultures.

Annexin V/Propidium Iodine Apoptosis Detection

Cells were treated for 4 days and each day they were subjected to Annexin V-FITC Apoptosis Detection kit (Enzo Life Science, Italy) to detect necrosis and to discriminate apoptotic cells by counterstaining with Propidium iodide using flow cytometry. After each treatment, $5*10^5$ cells/ml were washed in PBS and

resuspended in 195µl of Binding Buffer added with 5µl of Annexin V-FITC and incubated for 10 min at RT. Then cells were washed twice with PBS and resuspended in 190µl of Binding Buffer adding 10µl of Propidium Iodide (20µg/ml). Number of apoptotic and necrotic cells was determined by flow cytometer (PerkinElmer, Italy).

Gastric tissue sample

Human gastric tissue was collected by the Endoscopy Unit staff and by Surgery Unit at IRCCS Policlinico San Donato. Endoscopists provided biopsy samples of gastric mucosa which were classified as Normal, Gastritis and Neoplasia after pathologist evaluation. Biopsies were immediately frozen in liquid nitrogen for further analysis. Surgical samples were collected from patients undergoing surgical procedure for gastric cancer removal. Full thickness samples were collected after resection from neoplastic area and non-neoplastic one and placed in cold PBS with 1% antibiotic solution (100U/ml penicillin, 100mg/ml streptomycin). Samples were washed in PBS, cut in $0.5cm^3$ fragments and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS, 1% antibiotic solution (100U/ml penicillin, 100mg/ml streptomycin) at 37°C in a 5% CO_2 humidified atmosphere. Samples from neoplasia and healthy tissue were randomly assigned to be challenged with rhIL-33 (10ng/ml) or without challenge for 48h. After the treatment sample were frozen in liquid nitrogen for further analysis.

RNA extraction, RT and RealTime PCR

Total RNA samples were isolated from cells under various culture conditions by the use of a RNeasy kit (Qiagen, Italy), while total RNA was isolated from tissue samples by means of TRIzol® reagent (Life Technologies, Italy) following manufacturer's instructions.

One µg of total RNA from cells or tissues were subjected to DNase treatment (ThermoScientific, Italy) and then reverse transcribed using Oligo (dT)$_{18}$ primers and RevertAid H Minus First Strand cDNA Synthesis Kit (ThermoScientific, Italy). These cDNA preparations were subjected to quantitative RealTime-PCR using

Maxima SYBR Green qPCR Master Mix (Thermo Scientific, Italy)using specific target gene primers (Table 2), normalized to Human Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and ribosomal protein S14 and reported as relative-fold-change among groups, with baseline control set at 1

Statistical analysis

Statistical analysis was performed by GraphPad Prism 7 (GraphPad software, USA) using the appropriate statistical tests according to underlying distribution of data, with $p \leq 0.05$ considered statistically significant.

Ethical committee

The research was carried out according to The Code of Ethics of the World Medical Association - Declaration of Helsinki. The study protocol has been approved by the local Ethics Committee ASL Milano 2 (protocol n.2725). All patients enrolled have been informed about the study, and a written informed consent for the research use of samples was obtained before undergoing endoscopy or surgery.

Results

IL-33 expression is increased in chronic gastritis

Given the fact that IL-33 was shown to be overexpressed during chronic inflammation, we evaluate its expression gastric biopsies from patients who underwent EGDS procedures. Biopsies were collected and classified in Normal (HC; N=48) and Gastritis (G; N=55) (Table 1). Figure 1 showed that IL-33 is overexpressed in gastritis samples (1.75 ± 0.61; $p<0.05$).

IL-33 differentially modulates gastric cell proliferation

IL-33 treatment exerted opposite effects on the two cell lines considered. The gastric cancer AGS cell line proliferation was reduced after IL-33 exposure, while normal gastric GES-1 cell line proliferation was induced at the same experimental conditions.

More in details, the XTT proliferation assay on AGS cells showed a reduction of proliferation starting from day 3 of treatment with rhIL-33 10ng/ml (ctrl 0.2083±0.1414 vs. 10ng/ml 0.1494±0.0951; $p<0.05$). This trend was confirmed at day 4 of treatment which showed that proliferation was reduced for all rhIL-33 concentrations (ctrl 0.3242±0.1072 vs. 10ng/ml 0.2340±0.086 vs. 1ng/ml 0.2152±0.064 vs 0.1ng/ml 0.2293±0.083; $p<0.05$) (Fig. 2a).

To confirm that IL-33 could reduce AGS replication, we performed a scratch assay; wound closure was delayed when IL-33 was present, in a dose-dependent manner, starting from 6 hours, with IL-33 concentrations of 1ng/ml and 10ng/ml (ctrl 34.54% vs. 1ng/ml 3.89% $p<0.05$; ctrl 34.54% vs. 10ng/ml 2.55% $p<0.05$) (Fig. 2c).

Also, the CFSE assay showed a trend towards an inhibitory effect of IL-33 on AGS in a dose-dependent manner, but the data did not reach a statistical significance (Fig. 2e).

Conversely, the XTT proliferation assay on GES-1 cells showed an increase in proliferation starting from day 1 of treatment with rhIL-33 (ctrl 1.119±0.21 vs. 1ng/ml 1.263±0.159; $p<0.05$ and ctrl 1.119±0.21 vs. 0.1ng/ml 1.631±0.122; $p<0.05$). This trend was confirmed at day 2 (ctrl 0.076±0.03 vs. 10ng/ml 0.1262±0.122; $p<0.05$) (Fig.2b) and during the following 2 days of treatment when rhIL-33 increased the proliferation, but the data did not reach a statistical significance.

The proliferative effect was confirmed by the scratch assays, where wound closure was accelerated in a dose-dependent fashion with a concentration of 10ng/ml at 6 hours (ctrl 2.76%±2.0 vs. 10ng/ml 6.17%±1.9; $p<0.05$) (Fig.2d) and 24 hours timepoints (ctrl 15.67%±5.2 vs. 10ng/ml 26.93%±2.35; $p<0.05$) (Fig. 2d).

CFSE assay showed a trend towards an increased proliferation in IL-33 stimulated GES-1 with a dose-response correlation, but the data did not reach a statistical significance (Fig. 2f).

IL-33 induces apoptosis in gastric cancer cell line, but not in non-neoplastic cells

Apoptosis is another parameter evaluated in this study. Our experiments showed that IL-33 had different effects on different cell lines. In AGS evaluation of caspase-3 and caspase-7 activities showed an increase in apoptosis at 10ng/mL and 1ng/ml of IL-33 after 6h treatment (ctrl 8510±841 vs. 10ng/mL 10214±496 and

ctrl 8510±841 vs. 1ng/mL 12338±739; p<0.05) (Fig.3a). This data is confirmed by the Annexin V/Propidium Iodine assay, where IL-33 10ng/ml increased Annexin V at 24 hours treatment (ctrl 0.755%±0.31 vs. 10ng/ml 1.385%±1.16; p<0.05) (Fig. 3c), while Propidium Iodine remained unvaried (Fig.3e), indicating that IL-33 could induce apoptosis, but not necrosis in the cancer cell line.

In GES-1 evaluation of caspase-3 and caspase-7 activities did not show any variation in apoptosis (Fig. 3b). Annexin V/Propidium Iodine assay showed a reduction in Annexin V; however, this data reached a statistical significance only after 4 days of incubation with IL-33 0.1ng/ml e 10ng/ml (ctrl 0.33%±0.09 vs. 0.1ng/ml 0.11%±0.02; p<0.05; ctrl 0.33%±0.09 vs. 10ng/ml 0.09%±0.01; p<0.05, respectively) (Fig.3d); Propidium Iodine positive cells were reduced at 1ng/ml and 10ng/ml at day 1 (ctrl 0.55%±0.14 vs. 1ng/ml 0.36%±0.07; p<0.001; ctrl 0.55%±0.14 vs. 10ng/ml 0.31%±0.02; p<0.0001 and), day 3 (ctrl 0.282%±0.136 vs. 10ng/ml 0.165%±0.045; p<0.05 and ctrl 0.282%±0.136 vs. 1ng/ml 0.150%±0.045; p<0.05), and day 2 (ctrl 0.28%±0.14 vs. 1ng/ml 0.15%±0.06; p<0.05; ctrl 0.28%±0.14 vs. 10ng/ml 0.17%±0.04; p<0.05) (Fig.3f), indicating that IL-33 could reduce apoptosis and necrosis in the normal gastric epithelium cell line.

 IL-33 acts on cell cycle gene expression in gastric cell lines

In order to demonstrate the effect of IL-33 on the AGS and GES-1 cell cycle, we conducted a series of cytofluorometric analysis experiments after Propidium iodide staining with rhIL-33 stimulation. As shown in Figure 4a, in GES-1, IL-33 induces an increase in phase S at the expense of the other two, perhaps for a block between S phase and G2 phase; in particular non-stimulated GES-1 vs. IL-33 treated cells exhibit a percentage of G0/G1 transition cells of 59.4% vs. 47.5%, in phase S: 5.7% vs. 31.3%, and in G2/M transition: 28.7% vs. 17.8%. In AGS IL-33 seems to have the opposite effect, in fact there is a block between phases G1/G0 and S, and the latter decreases considerably after treatment at 24h that means that cells are not entering the S phase remaining in G1 phase; in particular non-stimulated AGS vs. IL-33 treated cells exhibit a percentage of G0/G1 transition cells: 49.9% vs. 59.9%, in phase S: 26.9% vs. 7.1%, and in G2/M transition: 19.4% vs. 26.7% (Fig.4b).

To explore further the potential molecular mechanisms underlying IL-33-mediated cell proliferation changes, we studied the expression of cell cycle. We compared GES-1 cells with AGS tumor cells, reporting the differential expression of six genes (Table 2). In particular, the cyclin C (CCNC), whose activation controls the transition G0/G1, and the cyclin E1 (CCNE1), whose activation promotes the G1/S transition, showed an increase of 6.11 and 6.04 times, respectively in AGS vs. GES-1 cells (p<0.05). Cellular regulatory genes such as BRCA and CDKN1A interacting protein (BCCIP), cyclin B1 (CCNB1) and Karyopherin 2 (KPNA2) genes involved in G2/M transition and DNA damage and repair control points increased by 2.34, 2.39 and 3.05 times, respectively in AGS vs. GES-1 cells (p<0.05). The expression of Caspase 3 (CASP3) was increased by 24.08 times (p<0.05) in AGS vs. GES-1 cells. Then cells were challenged for 24 hours with rhIL-33 (10ng/ml) and we observed that in AGS the stimulation with rhIL-33 decreased the expression of the selected genes, in particular, CCNC and CCNE1 showed a decrease of 3.31 and 4.15 times, respectively (p<0.001). BCCIP, CCNB1 decreased by 1.65 times (p<0.05). The expression of CASP3 was more than halved by the treatment by 10.57 times (p<0.05), suggesting IL-33 was promoting the initiation of the apoptotic cascade through the induction of caspase synthesis. In GES-1 the stimulation increased the expression of all the six genes considered but only KPNA1 reach a statistically significant modulation in comparison to untreated GES-1 cells (1.46 fold, p<0.05).

IL-33-stimulation of human gastric biopsies and surgical specimens modifies cell cycle gene expression

Before testing the cell cycle genes expression after the treatment with rhIL-33 on ex vivo samples we checked the expression of IL-33 and its receptor ST2 on biopsies collected from patients who underwent endoscopy and classified as Healthy Control (HC; N=48) and Gastric cancer patients (Neo; N=16) (Table 1). Results show that IL-33 is downregulated in Neo group vs. HC (0.53±0.30; p<0.001) (Fig.5a) while ST2L is upregulated in Gastric cancer patients (3.12±2.30; p<0.05) (Fig.5b).

To further explore the potential molecular effect of IL-33 on ex vivo human gastric tissues we first determine the expression by RT-PCR of the six genes identified in cell line profiler in biopsies from normal gastric tissue, and neoplastic tissue coming from different patients (Table 1). Figure 6 shows that all the

genes modulated in cell lines are overexpressed in gastric neoplasia samples (p<0.05), only BCCIP, even if overexpressed, does not reach a statistical significance (Fig. 6c).

Then we performed the same analysis on surgical specimen from patients with gastric cancer after stimulation with rh-IL-33 (10ng/ml) for 48h. Samples defined Healthy (HC) and Neoplastic (Neo) came from the same patient identifying with HC a region of stomach far from the region with neoplasia (Table 4). Figure 7 shows that all genes are overexpressed in HC tissue vs Neoplastic samples, in particular CASP3 (3.1±1.42 HC vs. 0.2±0.17 Neo; p<0.05). After treatment with rhIL-33 CASP3 is upregulated both in HC and Neoplastic samples, showing an effect on induction of apoptosis ex vivo (Fig.7a). In all the other genes the expression is downregulated in Neoplastic samples after treatment with rhIL-33 (Fig.7b-f) suggesting a role of this cytokine in the reduction of neoplastic cells proliferation. In normal tissue CCNC and CCNE1 were upregulated after treatment with rhIL-33 suggesting a role in induction of the transition of cells through G0/G1 and G1/S checkpoints (Fig.7e-f).

Discussion

The persistence of long-standing chronic inflammation is known to be of paramount importance in the development of gastric cancer; still, the precise role of each molecule participating to the pro-inflammatory mileu in chronic gastritis has still to be dissected. Herein, we confirm that IL-33 is highly expressed in gastric mucosa during gastritis and we identify diverging effects of this molecule on normal and neoplastic gastric epithelium. In fact, the incubation with rhIL-33 of GES-1 results in a significant cell proliferation increase, with no changes in apoptosis rates. These results are consistent with the observations that exposure to IL-33 causes histological changes in the lungs and GI tract, including epithelial cell hyperplasia and hypertrophy (5) and also metaplasia (4, 14, 21) and argue in favor of a role of IL-33 in the epithelial alterations preceding the neoplastic transformation.

By carrying out Real Time PCR and Western Blot, we have demonstrated the expression of the ST2 receptor in both cell lines (data not shown); this effect on proliferation of epithelial cells might be determined by direct action of IL-33 on the epithelial cells, given the expression of the ST2 receptor on the proliferating

epithelium. Unlike GES-1, the administration of rhIL-33 to AGS tumor cells leads to a reduction in proliferation, which is accompanied by an intensification of apoptosis. Overall, these results are of great interest, as they propose a direct antitumor action of the cytokine.

It is not the first time that IL-33 demonstrates antitumor properties, but previous studies suggested that those effects could be mediated mostly by the influence of cytokine on the immune system activation (22). Moreover, while the stimulation of cell proliferation has been demonstrated on different immune (23), stromal (24), epithelial (25) cell lines, an anti-proliferative effect of IL-33 is relatively new in the literature. It has been found only in two cases: on non-neoplastic murine fibroblastic cell line in a study conducted by Tominaga et al. (26), and on neoplastic pancreatic cells in a recent work by Fang et al. (27) in which they found that IL-33 is able to suppress cell proliferation only on quiescent cells, while it stimulates replication on proliferating cells. IL-33 appears to exert its effect only on cells in G0 phase suggesting the cytokine acts through a block between G0/G1 phase, that could be mediated by the increase of cell cycle inhibitory regulatory proteins (28). These observations are partially transferable to the cell lines used in our study. In fact, it can be speculated that IL-33 acts with anti-proliferative and pro-apoptotic effect only on the quiescent AGS, thus determining a significant reduction in replication, which however remains higher than that of normal GES-1. Our cytofluorimetric analysis of the cell cycle is consistent with the hypothesis of a block in G0/G1 transition. This test demonstrates a significant reduction in the percentage of cells in S phase in AGS, suggesting a block upstream of S phase, such as a block in G0/G1. Also the reduction of the expression of Cyclin C (CCNC) gene, necessary, together with the cyclin dependent kinase 3 (Cdk3), for the entry of quiescent cells in the G1 phase (29), could be responsible for this effect. CCNC, in fact, forms a complex with the Rb protein and Cdk3, triggering its enzymatic activity. The latter, then, phosphorylates the Rb protein inactivating it, which is sufficient for the cell to re-enter the cell cycle (30); that is probably because the hyperphosphorylated isoform of pRb loses affinity for E2F transcription factors, leaving them free to promote cell cycle progression (31). Additional genes we focused on are those that showed variations in opposite directions in normal and neoplastic cells, reflecting the dichotomic effects of IL-33.

In AGS cells, at baseline, these genes are expressed at much higher levels than in GES-1, as it can be expected in tumor cells, but treatment with rhIL-33 causes a significant decrease in the expression of each of them. This is consistent with the antiproliferative effect we observed on these cells. Whereas the reduction of CASP3 gene expression might be considered anti-apoptotic, it should not be forgotten that Caspases 3 and 7 demonstrated increased activity upon IL-33 administration, sufficient to support the pro-apoptotic effect of the cytokine. The reduction of CASP3 expression has instead an interesting implication in the effects on the cell cycle. In fact, Caspase 3 is also capable of cleaving p21 protein, repressor of the progression in the cell cycle, which acts on stimulation of the p53 protein, degrading the cyclin B, which is responsible for the G2/M transition. The same activity is performed by the BCCIP gene product, also downregulated in AGS. Consequently, the reduction of the expression of CASP3 and BCCIP would also result in a reduced degradation of p21 and consequently a greater inhibition of proliferation. Consistently, our results show the reduction of the mRNA of CCNB1, coding for cyclin B, target of p21. Data obtained on pancreatic cancer cells further support our results; in fact, pancreatic neoplastic cells show an increased expression of p53, p15 and p21, which are cell proliferation inhibitors (27). On the other hand, the expression of cell cycle progression-promoting genes, Cdk4 and Cdk2, decreased in pancreatic cells incubated with IL-33 (27). Cdk2 is the kinase that interacts with cyclin E, also downregulated in AGS, while Cdk4 binds to cyclin D, forming a further complex involved in the first phase G1 and potential site of the block of S phase in AGS. All these results prove to be coherent and complementary with ours and deserve further discussion

After having verified the expression of IL-33 and its receptor in gastric biopsies from healthy and neoplastic patients, we evaluated the expression of the cell cycle candidate genes before and after stimulation with the cytokine and , as Kania et al. (32) and Sun et al. (33) reported, we observed that CASP3 expression was decreased in patients with gastric tumors compared to that in patients with normal gastric tissue. The prognostic value of some proteins of the CASP family in gastric cancer (GC) and in particular of CASP3 was associated to favorable clinicopathological features and a positive prognosis after curative surgery (34). The 5-year overall survival rates of gastric cancer patients with higher expression of CASP3 were 51.2% (35).

From these evidence Caspase-3 may act as a tumor suppressor in human gastric cancer and data obtained by our ex vivo experiments shows that the effect of IL-33 on induction of CASP3 supports the potential role of IL-33 as anti-tumor factor. In gastric cancer, information about DNA copy number changes and gene expression changes showed differential gene expression between gastric tumor tissues and normal gastric tissues and the main genes are involved in basic functions such as the cell cycle, transcription, metabolism, signal transduction and DNA replication. CCNC is among the genes with reduced copy number and mRNA expression in gastric cancer vs. normal tissue (36). CCNC has been reported deleted in patients with acute lymphoblastic leukemia (37) supporting the possibility that the *CCNC* gene is closely linked to tumor suppressor genes. Our data showed that CCNC is downregulated in gastric neoplasia and also the treatment with rhIL-33 further reduced its expression.

Overall, our in vitro results demonstrate different IL-33 effects depending on the cell line: pro-proliferative on healthy gastric epithelial cells and anti-proliferative and pro-apoptotic on neoplastic gastric epithelium. The analysis of the underlying gene expression patterns supports a role of IL-33 in regulating cell cycle and apoptosis in gastric cancer tissue. In conclusion, the involvement of specific cell cycle regulators and apoptosis in the mechanisms of neoplastic transformation of gastric epithelial cells clearly emerges from this work. The ability of IL-33 to affect their expression is also demonstrated, probably by binding to its receptor, expressed by both normal and neoplastic epithelial cells. The antitumor action of IL-33 that emerged from the in vitro study has important clinical relevance; in fact, it offers evidence to support a possible use of the cytokine in immunotherapy against gastric adenocarcinoma, a therapeutic field that is going through a phase of great dynamism (38). It could thus respond to the urgency of identifying new and more effective weapons against this neoplasm. In fact, in the Western countries the decrease in gastric adenocarcinoma mortality observed recently depends more on the reduction of the incidence than on the improvement of the treatment. Because of the difficulty of implementing screening programs in the West, gastric cancer is mainly diagnosed in the advanced stage, resulting in a negative prognosis (39). However, we must not forget that the opposite stimulating effects of proliferation observed on gastric epithelial cells could mean a pro-tumorigenic effect on the normal epithelium. Consequently, it is important to further

dissect the molecular pathways involved in order to identify the correct targets for a possible therapeutic manipulation of the IL-33/ST2 axis.

Author Contributions

Conceptualization, Laura Francesca Pisani; Funding acquisition, Maurizio Vecchi and Luca Pastorelli; Investigation, Laura Francesca Pisani, Beatrice Marinoni, Isabella Teani, Nicoletta Nandi and Pasquale Creo; Resources, Laura Francesca Pisani, Gianeugenio Tontini, Carmine Gentile, Beatrice Marinoni and Emanuele Asti; Supervision, Luca Pastorelli; Writing – original draft, Laura Francesca Pisani; Writing – review & editing, Luigi Bonavina, Maurizio Vecchi and Luca Pastorelli.

Conflicts of Interest

None of the authors have any conflicts of interest related to this article to declare.

Financial support

This work was supported in part by the SIGE - Società Italiana di Gastroenterologia ed Endoscopia Digestiva - Italian Society of Gastroenterology and Digestive Endoscopy Research Grant

References

1.   Carcas LP. Gastric cancer review. J Carcinog. 2014;13:14.
2.   Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012;4(7):156-69.
3.   Wasmer MH, Krebs P. The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Front Immunol. 2016;7:682.
4.   Petersen CP, Meyer AR, De Salvo C, Choi E, Schlegel C, Petersen A, et al. A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut. 2017.
5.   Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90.
6.   Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14(5):408-19.
7.   Fagundes CT, Amaral FA, Souza AL, Vieira AT, Xu D, Liew FY, et al. ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion. J Leukoc Biol. 2007;81(2):492-9.

8.   Lopetuso LR, De Salvo C, Pastorelli L, Rana N, Senkfor HN, Petito V, et al. IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proc Natl Acad Sci U S A. 2018;115(40):E9362-E70.

9.   Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DM, Artis D. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci U S A. 2015;112(34):10762-7.

10.   Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8(1):22.

11.   Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A. 2010;107(17):8017-22.

12.   Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol. 2008;180(4):2443-9.

13.   Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367-70.

14.   De Salvo C, Pastorelli L, Petersen CP, Buttò LF, Buela KA, Omenetti S, et al. IL-33 triggers early eosinophil-dependent events leading to metaplasia in a chronic model of gastritis-prone mice. Gastroenterology. 2020.

15.   da Silva EAW, da Silva NMJW, Rodrigues RR, Adad SJ, de Lima Pereira SA, Ribeiro BM, et al. Arginase-1 and Treg Profile Appear to Modulate Inflammatory Process in Patients with Chronic Gastritis:. Mediators Inflamm. 2019;2019:2536781.

16.   Buzzelli JN, Chalinor HV, Pavlic DI, Sutton P, Menheniott TR, Giraud AS, et al. IL33 Is a Stomach Alarmin That Initiates a Skewed Th2 Response to Injury and Infection. Cellular and Molecular Gastroenterology and Hepatology. 2015;1:203-21.

17.   Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med (Berl). 2016;94(5):535-43.

18.   Yu XX, Hu Z, Shen X, Dong LY, Zhou WZ, Hu WH. IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway. Dig Dis Sci. 2015;60(5):1265-72.

19.   Ye XL, Zhao YR, Weng GB, Chen YC, Wei XN, Shao JP, et al. IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep. 2015;33(6):2746-52.

20.   Hu W, Li X, Li Q, Tan Y, Xu B, Xie Q, et al. Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients. Pathol Oncol Res. 2017;23(3):615-9.

21.   Buzzelli JN, Chalinor HV, Pavlic DI, Sutton P, Menheniott TR, Giraud AS, et al. IL33 Is a Stomach Alarmin That Initiates a Skewed Th2 Response to Injury and Infection. Cell Mol Gastroenterol Hepatol. 2015;1(2):203-21.e3.

22.   Gao X, Wang X, Yang Q, Zhao X, Wen W, Li G, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol. 2015;194(1):438-45.

23.   Tong X, Barbour M, Hou K, Gao C, Cao S, Zheng J, et al. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol Oncol. 2016;10(1):113-25.

24.   Bianchetti L, Marini MA, Isgrò M, Bellini A, Schmidt M, Mattoli S. IL-33 promotes the migration and proliferation of circulating fibrocytes from patients with allergen-exacerbated asthma. Biochem Biophys Res Commun. 2012;426(1):116-21.

25.   Saluja R, Hawro T, Eberle J, Church MK, Maurer M. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. J Biol Regul Homeost Agents. 2014;28(4):575-85.

26.   Tominaga S, Tago K, Tsuda H, Komine M. Dual function of IL-33 on proliferation of NIH-3T3 cells. Cytokine. 2015;72(1):105-8.

27.   Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, et al. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med Oncol. 2017;34(2):23.

28.   Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295-312.

29.   Sage J. Cyclin C makes an entry into the cell cycle. Dev Cell. 2004;6(5):607-8.

30.   Sage J, Miller AL, Pérez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 2003;424(6945):223-8.

31.   Ren S, Rollins BJ. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell. 2004;117(2):239-51.

32.   Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC. Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci. 2003;48(2):266-71.

33.   Sun Y, Chen XY, Liu J, Cheng XX, Wang XW, Kong QY, et al. Differential caspase-3 expression in noncancerous, premalignant and cancer tissues of stomach and its clinical implication. Cancer Detect Prev. 2006;30(2):168-73.

34.   Wang Z, Ni F, Yu F, Cui Z, Zhu X, Chen J. Prognostic significance of mRNA expression of CASPs in gastric cancer. Oncol Lett. 2019;18(5):4535-54.

35.   Huang KH, Fang WL, Li AF, Liang PH, Wu CW, Shyr YM, et al. Caspase-3, a key apoptotic protein, as a prognostic marker in gastric cancer after curative surgery. Int J Surg. 2018;52:258-63.

36.   Yang S, Jeung HC, Jeong HJ, Choi YH, Kim JE, Jung JJ, et al. Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Genomics. 2007;89(4):451-9.

37.   Li H, Lahti JM, Valentine M, Saito M, Reed SI, Look AT, et al. Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics. 1996;32(2):253-9.

38.   Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74.

39.   Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.

Table 1: Demographic of patients enrolled for bioptic specimen collection

Group	N	Gender	n (%)	Age (mean±SD)
Healthy Controls (HC)	48	F	33 (68,8)	60,7 ± 15,1
		M	15 (31,3)	
Gastritis (G)	55	F	35 (63,4)	60,5 ± 16,1
		M	20(36,4)	
Neoplasia (Neo)	16	F	10 (62,5)	75,6 ± 8,1
		M	6 (37,5)	

Table 2: Cell cycle genes differentially regulated in GES-1 and AGS cells after rhIL-33 stimulation. Using GES-1 as control cell line we selected a subset of genes that are differentially regulated between the two cell lines.

Gene Symbol	Fold change				p-value		
	GES-1	GES-1 + rhIL-33	AGS	AGS + rhIL-33	GES-1 + rhIL-33	AGS	AGS + rhIL-33
BCCIP	1,000	1,453	**2,395**	**1,649**	0,281	*0,002*	*0,019*
CASP3	1,000	1,818	**24,084**	**10,566**	0,141	*0,00003*	*0,010*
CCNB1	1,000	1,446	**2,389**	**1,653**	0,284	*0,002*	*0,019*
CCNC	1,000	1,473	**6,105**	**3,313**	0,265	0,053	*0,0004*
CCNE1	1,000	1,153	**6,035**	**4,145**	0,576	*0,0001*	*0,0001*
KPNA2	1,000	1,456	**3,046**	1,039	*0,006*	*0,0002*	0,744

Table 3: Primer pairs used for cDNA amplification of genes differentially expressed in the two cell lines.

Gene	Forward	Revers
human IL-33	GACTCCTCCGAACACAGAGC	TGCTTGCTGTGTTCTTCCAC
human ST2L	TTGCAAGGACAGCATCAAAG	GTCTGTGTTCCTGCCCAAAT
human CASP3	ACATCTCGGTCTGGTACAG	ACATCACGCATCAATTCCAC
human KPNA2	GTTGGCTCTCCTTGCAGTTC	GGGGTGCAGGATTCTTGTTG
human BCCIP	GAACTCGCGGTCACAGTACT	CACATGCGCTGATCAGTAGG
human CCNC	CTAGCCCAGCCTAGCAGAAA	ACTTCATGTAGTTTGCCCAGC
human CCNE1	CTCTTCTGTCTGTTGCAGCG	TTGCCCTGTTTGATGCCATC
human CCNB1	GGTTGTTGCAGGAGACCATG	AACATGGCAGTGACACCAAC
human GAPDH	CCATCACCATCTTCCAGGAG	CCTGCTTCACCACCTTCTTG
human S14	GTGTGACTGGTGGGATGAAGG	TTGATGTGTAGGGCGGTGATAC

Table 4: Demographic of patients who underwent surgical procedure

Group	N	Gender	n (%)	Age (mean±SD)
Surgical sample	3	F	2 (75)	75 ± 11.5
		M	1 (25)	

Figure Legends

Figure 1: Expression of IL-33 in gastric biopsies: Data are shown as mean±sd. HC: Healthy Controls. * p<0.05.

Figure 2: Proliferation assays. a) XTT, c) Wound healing   and e) CFSE assays on AGS cells show a decreased proliferation after IL-33 treatment. The same assays (b, d, f respectively) show the opposite effect on GES-1 cells, IL-33 can induce proliferation. Data are shown as mean±sd.* $p<0.05$.

Figure 3: Apoptosis assays. a) Caspase 3/7 activity and (c-e) Annexin V/Propidium Iodine assays show that

IL-33 can induce apoptosis in AGS cells, while by means of the same assays (b, d, f, respectively) IL-33 can

reduce GES-1 apoptosis. Data are shown as mean±sd. * p<0.05. ** p<0.001

Figure 4: Cell cycle analysis by Propidium Iodine staining. Cell cycle is impaired by IL-33 treatment in both cell lines. a) In GES-1 IL-33 induces an increase in phase S at the expense of the other two, perhaps for a block between S phase and G2 phase; b) In AGS IL-33 seems to block cells between phases G1/G0 and S, and the latter decreases considerably after treatment at 24h. Data are shown as mean of % of gated cells.

Figure 5: Expression of IL-33 and its receptor ST2 in gastric biopsies: a) IL-33 is downregulated in neoplastic biopsies while b) its receptor ST2 is overexpressed in gastric cancer biopsies vs. healthy controls . Data are shown as mRNA Fold change ± sd. HC: Healthy control; Neo: Gastric cancer biopsies. * $p<0.05$; ** $p<0.001$.

Figure 6: Gene expression in gastric biopsies. Cell cycle genes are overexpressed in gastric cancer biopsies vs. healthy controls. Data are shown as mRNA Fold change ± sd. HC: Healthy control; Neo: Gastric cancer biopsies. * p<0.05.

Figure 7: Gene expression in surgical specimen from gastric cancer patients with or without rhIL-33 treatment. Cell cycle genes are modulated both in HC and   in gastric cancer   after treatment with rhIL-33 for 48h. Data are shown as mRNA Fold change ± sd. HC: Healthy control; HC + rhIL-33: healthy control treated with IL-33; Neo: Gastric cancer tissue; Neo + rhIL-33: Gastric cancer tissue treated with IL-33. * p<0.05.

Figure 8: Schematic representation of cell cycles gene modulated by IL-33. a) in AGS IL-33 interact with gene which block G0/G1 transition and G2/M transition leading to a reduction of cell proliferation, while b) the induction of the overexpression of the same genes in GES-1 leads to an increase in proliferation.